Pharmaniaga Records Higher Net Profit In 1Q

KUALA LUMPUR, May 7 (Bernama) -- Pharmaniaga Bhd recorded a net profit of RM29.58 million in the first quarter ended March 31, 2025 (1Q), up from RM25.65 million in the same period last year.

Revenue in the quarter rose 9.4 per cent to RM1.06 billion compared to RM964.96 million previously, the company said in a filing with Bursa Malaysia.

The growth in revenue was primarily driven by higher demand in the concession segment, attributed to higher volume of orders from government hospitals and the addition of new products to the Approved Products Purchase List.

Managing director Zulkifli Jafar said the group continues to deliver consistent performance across all business segments, and has achieved several important milestones in its biopharmaceutical sector, including the launch of its first flu vaccine and entry into the insulin market.

The group is making significant progress in expanding its non-concession government business. It secured two major tenders from the Ministry of Health for the supply of high-value specialty injectable medicines worth RM97.5 million over three years.

“Additionally, Pharmaniaga secured a RM139.0 million contract to supply dialysis solutions for the Social Security Organisation through 2029, reflecting continued market confidence in the group’s capabilities,” he said in a statement today.

bootstrap slideshow

“Our biopharmaceutical momentum is also gaining traction, with the award of the RM3.0 million human insulin supply contract from teaching hospitals under the Ministry of Higher Education,” he added.

In Indonesia, the group has commenced contract manufacturing activities with several reputable companies under Contract Development and Manufacturing Organisation (CDMO).

“To grow the manufacturing business, we have adopted a dual-country approach, replicating successful initiatives from Malaysia in Indonesia. 

“By sharing expertise and best practices across both markets, our Indonesia division benefits from Malaysia’s research and development through technology transfer, while delivering the latest pharmaceutical products to the market,” he said.

The group is moving forward with the implementation of its Regularisation Plan to exit its Practice Note 17 (PN17) status, following shareholders’ approval of resolutions at the extraordinary general meeting (EGM) held on March 20, 2025.

With strategic initiatives in motion, Pharmaniaga added that it remains focused on delivering its growth targets for 2025 and reinforcing its market position across core business segments.

-- BERNAMA